Literature DB >> 15271674

Emerging role of relaxin in renal and cardiovascular function.

Kirk P Conrad1, Jacqueline Novak.   

Abstract

Although traditionally associated with reproductive processes, relaxin is emerging as an important player in renal and cardiovascular function. Much of our recently acquired understanding of relaxin in this new context has arisen from studies of maternal renal and cardiovascular adaptations to pregnancy in rats where the hormone is turning out to be an important mediator. First, we highlight the influence of relaxin on renal hemodynamics and glomerular filtration rate, as well as on other peripheral circulations. Second, we discuss the effect of relaxin on both the steady and pulsatile systemic arterial load, as well as on the heart, in particular, coronary blood flow. Third, we consider the impact of the hormone on cultured endothelial and vascular smooth muscle cells. Fourth, we address the interaction of relaxin with renal and cardiac disease, as well as its role in angiogenesis. Finally, in Perspectives, we point out several key research questions in need of investigation that relate to a potential autocrine/paracrine role of relaxin in renal and cardiovascular tissues. Furthermore, on the basis of its potent vasodilatory and matrix-degrading attributes, we speculate about the therapeutic potential of relaxin in renal and cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15271674     DOI: 10.1152/ajpregu.00672.2003

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  36 in total

Review 1.  [The heart during pregnancy].

Authors:  Michael E Hall; Eric M George; Joey P Granger
Journal:  Rev Esp Cardiol       Date:  2011-10-01       Impact factor: 4.753

Review 2.  Relaxin family peptide receptors--former orphans reunite with their parent ligands to activate multiple signalling pathways.

Authors:  M L Halls; E T van der Westhuizen; R A D Bathgate; R J Summers
Journal:  Br J Pharmacol       Date:  2007-02-12       Impact factor: 8.739

Review 3.  The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.

Authors:  Jennifer M Sasser
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

Review 4.  Cardiovascular effects of relaxin: from basic science to clinical therapy.

Authors:  Xiao-Jun Du; Ross A D Bathgate; Chrishan S Samuel; Anthony M Dart; Roger J Summers
Journal:  Nat Rev Cardiol       Date:  2009-11-24       Impact factor: 32.419

Review 5.  Relaxin: antifibrotic properties and effects in models of disease.

Authors:  Chrishan S Samuel
Journal:  Clin Med Res       Date:  2005-11

Review 6.  Constitutive formation of an RXFP1-signalosome: a novel paradigm in GPCR function and regulation.

Authors:  Michelle L Halls
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 7.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 8.  Relaxin: review of biology and potential role in treating heart failure.

Authors:  Sam L Teichman; Elaine Unemori; John R Teerlink; Gad Cotter; Marco Metra
Journal:  Curr Heart Fail Rep       Date:  2010-06

9.  Does glomerular hyperfiltration in pregnancy damage the kidney in women with more parities?

Authors:  Ilknur Inegol Gumus; Ebru Uz; Nuket Bavbek; Ayse Kargili; Burcu Yanik; Faruk Hilmi Turgut; Ali Akcay; Nilgun Ozturk Turhan
Journal:  Int Urol Nephrol       Date:  2009-07-04       Impact factor: 2.370

Review 10.  Relaxin, a pleiotropic vasodilator for the treatment of heart failure.

Authors:  Sam L Teichman; Elaine Unemori; Thomas Dschietzig; Kirk Conrad; Adriaan A Voors; John R Teerlink; G Michael Felker; Marco Metra; Gad Cotter
Journal:  Heart Fail Rev       Date:  2008-12-20       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.